Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Fujiwara

Showing results (111-120 of 176) with videos related to

Pageof 18
Sort By:
Molecular and Clinical Oncology|November 15, 2021
Prognostic significance of the number of removed lymph nodes according to FIGO stage in ovarian clear cell carcinomaKohei Tamura, Yuji Takei, Shigeki Matsubara, et al.
Oncology Letters|July 12, 2012
Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinomaHiroyuki Fujiwara, Toshiko Jobo, Yuji Takei, et al.
Congenital Anomalies|April 19, 2024
A novel variant in IFT122 associated with a severe phenotype of cranioectodermal dysplasiaShiho Nagayama, Hironori Takahashi, Fuyuki Hasegawa, et al.
International Journal of Oncology|November 27, 2010
Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotionHiroaki Nonaka, Yasushi Saga, Hiroyuki Fujiwara, et al.
The Journal of Obstetrics and Gynaecology Research|August 17, 2016
Prognosis of endometrial cancer patients with and without symptoms at recurrenceTakahiro Yoshiba, Yuji Takei, Shizuo Machida, et al.
Cancer Science|February 20, 2016
Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factorsYoshifumi Takahashi, Yasushi Saga, Takahiro Koyanagi, et al.
International Journal of Clinical Oncology|April 22, 2018
Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinomaYuji Takei, Suzuyo Takahashi, Shizuo Machida, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 11, 2015
Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approachHiroaki Itamochi, Nao Oumi, Tetsuro Oishi, et al.
International Journal of Molecular Sciences|November 27, 2025
Determination of the Number of Circulating Small Extracellular Vesicles in Pregnancy Using the Novel Marker CD9Risa Narumi, Hirotada Suzuki, Manabu Ogoyama, et al.
International Journal of Oncology|October 14, 2015
The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survivalYoshifumi Takahashi, Yasushi Saga, Takahiro Koyanagi, et al.
Pageof 18

Showing results (111-120 of 176) with videos related to

Sort By:
Pageof 18
Molecular and Clinical Oncology|November 15, 2021
Prognostic significance of the number of removed lymph nodes according to FIGO stage in ovarian clear cell carcinomaKohei Tamura, Yuji Takei, Shigeki Matsubara, et al.
Oncology Letters|July 12, 2012
Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinomaHiroyuki Fujiwara, Toshiko Jobo, Yuji Takei, et al.
Congenital Anomalies|April 19, 2024
A novel variant in IFT122 associated with a severe phenotype of cranioectodermal dysplasiaShiho Nagayama, Hironori Takahashi, Fuyuki Hasegawa, et al.
International Journal of Oncology|November 27, 2010
Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotionHiroaki Nonaka, Yasushi Saga, Hiroyuki Fujiwara, et al.
The Journal of Obstetrics and Gynaecology Research|August 17, 2016
Prognosis of endometrial cancer patients with and without symptoms at recurrenceTakahiro Yoshiba, Yuji Takei, Shizuo Machida, et al.
Cancer Science|February 20, 2016
Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factorsYoshifumi Takahashi, Yasushi Saga, Takahiro Koyanagi, et al.
International Journal of Clinical Oncology|April 22, 2018
Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinomaYuji Takei, Suzuyo Takahashi, Shizuo Machida, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 11, 2015
Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approachHiroaki Itamochi, Nao Oumi, Tetsuro Oishi, et al.
International Journal of Molecular Sciences|November 27, 2025
Determination of the Number of Circulating Small Extracellular Vesicles in Pregnancy Using the Novel Marker CD9Risa Narumi, Hirotada Suzuki, Manabu Ogoyama, et al.
International Journal of Oncology|October 14, 2015
The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survivalYoshifumi Takahashi, Yasushi Saga, Takahiro Koyanagi, et al.
Pageof 18